Rhythm Pharmaceuticals (RYTM) Liabilities and Shareholders Equity (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $442.3 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $442.3 million, up 14.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 18.22% YoY), and the FY2025 annual result was $480.2 million, up 22.41% from the prior year.
• Liabilities and Shareholders Equity eased to $442.3 million in Q1 2026 per RYTM's latest filing, from $480.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $506.9 million in Q3 2025 and troughed at $258.7 million in Q1 2024.
• A 5-year average of $368.4 million and a median of $372.7 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity sank 32.54% in 2022, then soared 49.5% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $382.5 million in 2022, then retreated by 13.0% to $332.7 million in 2023, then rose by 17.89% to $392.3 million in 2024, then advanced by 22.41% to $480.2 million in 2025, then declined by 7.89% to $442.3 million in 2026.
• Business Quant data shows RYTM's Liabilities and Shareholders Equity at $442.3 million in Q1 2026, $480.2 million in Q4 2025, and $506.9 million in Q3 2025.